BlackRock’s Evoke Pharma EVOK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-122
| Closed | -$606 | – | 5565 |
|
|
2025
Q3 | $606 | Hold |
122
| – | – | ﹤0.01% | 5364 |
|
|
2025
Q2 | $317 | Hold |
122
| – | – | ﹤0.01% | 5388 |
|
|
2025
Q1 | $336 | Hold |
122
| – | – | ﹤0.01% | 5362 |
|
|
2024
Q4 | $539 | Hold |
122
| – | – | ﹤0.01% | 5325 |
|
|
2024
Q3 | $581 | Hold |
122
| – | – | ﹤0.01% | 5151 |
|
|
2024
Q2 | $774 | Hold |
122
| – | – | ﹤0.01% | 5212 |
|
|
2024
Q1 | $893 | Sell |
122
-1
| -0.8% | -$8 | ﹤0.01% | 5208 |
|
|
2023
Q4 | $1.55K | Hold |
123
| – | – | ﹤0.01% | 5251 |
|
|
2023
Q3 | $2.03K | Hold |
123
| – | – | ﹤0.01% | 5299 |
|
|
2023
Q2 | $2.43K | Hold |
123
| – | – | ﹤0.01% | 5359 |
|
|
2023
Q1 | $2.8K | Sell |
123
-526
| -81% | -$20.6K | ﹤0.01% | 5422 |
|
|
2022
Q4 | $20.9K | Sell |
649
-16
| -2% | -$353 | ﹤0.01% | 5369 |
|
|
2022
Q3 | $15K | Sell |
665
-24
| -3% | -$789 | ﹤0.01% | 5552 |
|
|
2022
Q2 | $27K | Sell |
689
-541
| -44% | -$25.8K | ﹤0.01% | 5515 |
|
|
2022
Q1 | $88K | Sell |
1,230
-22
| -2% | -$1.75K | ﹤0.01% | 5308 |
|
|
2021
Q4 | $100K | Buy |
1,252
+33
| +3% | +$4.62K | ﹤0.01% | 5274 |
|
|
2021
Q3 | $228K | Buy |
1,219
+103
| +9% | +$17.4K | ﹤0.01% | 4952 |
|
|
2021
Q2 | $221K | Buy |
1,116
+68
| +6% | +$14.6K | ﹤0.01% | 4881 |
|
|
2021
Q1 | $276K | Buy |
1,048
+79
| +8% | +$31.6K | ﹤0.01% | 4688 |
|
|
2020
Q4 | $360K | Buy |
969
+78
| +9% | +$40.2K | ﹤0.01% | 4395 |
|
|
2020
Q3 | $601K | Sell |
891
-494
| -36% | -$315K | ﹤0.01% | 4229 |
|
|
2020
Q2 | $706K | Buy |
1,385
+965
| +230% | +$268K | ﹤0.01% | 4138 |
|
|
2020
Q1 | $70K | Buy |
420
+31
| +8% | +$5.95K | ﹤0.01% | 4411 |
|
|
2019
Q4 | $91K | Buy |
389
+7
| +2% | +$1.2K | ﹤0.01% | 4459 |
|
|
2019
Q3 | $47K | Buy |
382
+23
| +6% | +$3.08K | ﹤0.01% | 4547 |
|
|
2019
Q2 | $32K | Sell |
359
-229
| -39% | -$22.7K | ﹤0.01% | 4635 |
|
|
2019
Q1 | $127K | Buy |
588
+8
| +1% | +$2.73K | ﹤0.01% | 4337 |
|
|
2018
Q4 | $207K | Buy |
580
+30
| +5% | +$11.1K | ﹤0.01% | 4225 |
|
|
2018
Q3 | $236K | Buy |
550
+20
| +4% | +$7.98K | ﹤0.01% | 4282 |
|
|
2018
Q2 | $191K | Buy |
530
+71
| +15% | +$26.6K | ﹤0.01% | 4312 |
|
|
2018
Q1 | $138K | Buy |
459
+4
| +0.9% | +$1.32K | ﹤0.01% | 4282 |
|
|
2017
Q4 | $148K | Buy |
455
+22
| +5% | +$9.12K | ﹤0.01% | 4269 |
|
|
2017
Q3 | $209K | Buy |
433
+10
| +2% | +$3.86K | ﹤0.01% | 4217 |
|
|
2017
Q2 | $156K | Buy |
423
+133
| +46% | +$50.9K | ﹤0.01% | 4317 |
|
|
2017
Q1 | $130K | Buy |
+290
| New | +$119K | ﹤0.01% | 4291 |
|
BlackRock's EVOK Position: Q4 2025 in Review
BlackRock sold out of Evoke Pharma (EVOK) in Q4 2025, closing a stake of 122 shares — an estimated $606 sold.
BlackRock first reported a position in EVOK in Q1 2017 and held it in 35 quarters. The position peaked at $706K in Q2 2020. 0 funds tracked by Wall St. Rank hold EVOK as of Q4 2025.
- BlackRock reported no remaining Evoke Pharma position as of Q4 2025 after selling out during the quarter.
- BlackRock sold 122 Evoke Pharma shares in Q4 2025, an estimated $606.
- BlackRock first reported a position in Evoke Pharma in Q1 2017 and held it in 35 quarters.
- BlackRock's Evoke Pharma position peaked at $706K in Q2 2020.
- 0 funds tracked by Wall St. Rank held Evoke Pharma as of Q4 2025.
Based on BlackRock's 13F filing for Q4 2025, filed 12 Feb 2026.